Pathogenic variants in AKT serine/threonine kinase 1 (AKT1), an oncogenic component of the (PI3K)-AKT-mTOR pathway, have been identified in non-NF2 meningiomas of the medial skull base [18, 27, 37]. This evidence concerns the gene AKT1 and meningioma.